8 June 2021

Jeroen Creemers and Johannes Textor, theme Cancer development and immune defense, published in the Journal for ImmunoTherapy of Cancer. Using a computational modeling approach, they showed that a tipping point - a sharp state transition between immune control and immune evasion - has major consequences for responses to immune checkpoint inhibitors and patient survival.

Background: Predicting treatment response or survival of cancer patients remains challenging in immuno-oncology. Efforts to overcome these challenges focus, among others, on the discovery of new biomarkers. Despite advances in cellular and molecular approaches, only a limited number of candidate biomarkers eventually enter clinical practice.

Methods: A computational modeling approach based on ordinary differential equations was used to simulate the fundamental mechanisms that dictate tumor-immune dynamics and to investigate its implications on responses to immune checkpoint inhibition (ICI) and patient survival. Using in silico biomarker discovery trials, we revealed fundamental principles that explain the diverging success rates of biomarker discovery programs.

Results: Our model shows that a tipping point-a sharp state transition between immune control and immune evasion-induces a strongly non-linear relationship between patient survival and both immunological and tumor-related parameters. In patients close to the tipping point, ICI therapy may lead to long-lasting survival benefits, whereas patients far from the tipping point may fail to benefit from these potent treatments.

Conclusion: These findings have two important implications for clinical oncology. First, the apparent conundrum that ICI induces substantial benefits in some patients yet completely fails in others could be, to a large extent, explained by the presence of a tipping point. Second, predictive biomarkers for immunotherapy should ideally combine both immunological and tumor-related markers, as a patient's distance from the tipping point can typically not be reliably determined from solely one of these. The notion of a tipping point in cancer-immune dynamics helps to devise more accurate strategies to select appropriate treatments for patients with cancer.

 

Related news items


Radboud university medical center and Astherna join forces for new therapy for Stargardt disease

17 June 2021

RNA therapy for patients with a severe inherited retinal disease

read more

The international dataset for colorectal local excisions is published

16 June 2021

Iris Nagtegaal and colleagues presented their first paper on the colorectal cancer dataset and published this in the journal Gastroenterology.

read more

Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis

15 June 2021

Intan Dewi and Frank van de Veerdonk published in Cell Reports Medicine that Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis.

read more

ZonMw Open Competition Grants for several Radboud researchers

15 June 2021

Four teams including researchers from Radboudumc and Radboud University receive a ZonMw Open Competion grant. Each proposal has a maximum budget of 750K euros.

read more

ZonMw Open Competition Grant for Annemiek van Spriel and Piet Gros

15 June 2021

Annemiek van Spriel, theme cancer development and immune defense, together with Piet Gros, Dept. of Chemistry, Utrecht University obtained a ZonMw Open Competition Grant to investigate IL-6 receptor structure and signalling in tumor cells.

read more